TP53 and B-cell chronic lymphocytic leukemia: Recently it has been reported that the TP53 mutation/17pdel combination, which represents a major determinant of resistance to immune-chemotherapy in B-CLL [10], might negatively interferes also with Ibrutinib efficacy [11, 12].